NXTCL — NextCell Pharma AB Share Price
Last trade - 00:00- SEK46.24m
- SEK5.81m
- SEK10.11m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.7 | ||
| Price to Tang. Book | 0.7 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.78 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -60.68% | ||
| Return on Equity | -47.16% | ||
| Operating Margin | -344.34% | ||
Financial Summary
| Year End 31st Aug | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 1.81 | 3.56 | 3.91 | 5.59 | 10.11 | n/a | n/a | 72.85% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NextCell Pharma AB, formerly Cellaviva AB, is a Sweden-based biopharmaceutical company. The Company is focusing on research and development of stem cell therapies and is also running a tissue establishment and biobank, classified as healthcare provider. NextCell's business concept is to develop and commercialize mesenchymal stem cell products based on the Company's proprietary selection algorithm, primarily for the treatment of autoimmune diabetes, as well as other types of autoimmune diseases.
Directors
- Last Annual
- August 31st, 2023
- Last Interim
- November 30th, 2023
- Incorporated
- March 19th, 2014
- Public Since
- July 13th, 2017
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 34,379,523
- Address
- Karolinska Institutet Science Park, HUDDINGE, 141 57
- Web
- https://www.nextcellpharma.com/
- Phone
- +46 87355595
- Auditors
- Ohrlings PricewaterhouseCoopers AB
Upcoming Events for NXTCL
Similar to NXTCL
2cureX AB
OMX Nordic Exchange Stockholm
Abliva AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
AddLife AB
OMX Nordic Exchange Stockholm
FAQ
As of Today at 19:15 UTC, shares in NextCell Pharma AB are trading at SEK1.35. This share price information is delayed by 15 minutes.
Shares in NextCell Pharma AB last closed at SEK1.35 and the price had moved by -77.73% over the past 365 days. In terms of relative price strength the NextCell Pharma AB share price has underperformed the FTSE Global All Cap Index by -79.6% over the past year.
There is no consensus recommendation for this security.
NextCell Pharma AB does not currently pay a dividend.
NextCell Pharma AB does not currently pay a dividend.
NextCell Pharma AB does not currently pay a dividend.
To buy shares in NextCell Pharma AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK1.35, shares in NextCell Pharma AB had a market capitalisation of SEK46.24m.
Here are the trading details for NextCell Pharma AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: NXTCL
Based on an overall assessment of its quality, value and momentum NextCell Pharma AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like NextCell Pharma AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -62.16%.
As of the last closing price of SEK1.35, shares in NextCell Pharma AB were trading -56.69% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The NextCell Pharma AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK1.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on NextCell Pharma AB's directors